Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8

Leukemia volume 28, pages 1754–1758 (2014)Cite this article

Subjects

Trisomy 8 (+8) is the most frequent numerical chromosome aberration in acute myeloid leukemia (AML), occurring in ∼9% of adult patients.1 In one-third of such patients, +8 is the sole cytogenetic abnormality.1 These patients are mostly classified as having an intermediate prognosis.1, 2 The few available studies suggest that sole +8 AML is molecularly heterogeneous,3, 4, 5 but the clinical impact of mutations remains to be established. Moreover, although the biologic features of sole +8 AML have been investigated using genome-wide gene-6, 7 or microRNA-expression8 analyses, these studies included small numbers of patients.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

  1. Mrózek K, Heerema NA, Bloomfield CD . Cytogenetics in acute leukemia. Blood Rev 2004; 18: 115–136.

    Article  Google Scholar 

  2. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453–474.

    Article  Google Scholar 

  3. Rocquain J, Carbuccia N, Trouplin V, Raynaud S, Murati A, Nezri M et al. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer 2010; 10: 401.

    Article  Google Scholar 

  4. Caramazza D, Lasho TL, Finke CM, Gangat N, Dingli D, Knudson RA et al. IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia [letter]. Leukemia 2010; 24: 2120–2122.

    Article  CAS  Google Scholar 

  5. Alpermann T, Haferlach C, Eder C, Kohlmann A, Kern W, Haferlach T et al. Sole trisomy 8 in AML: concomitant molecular markers, stability of genetic patterns and impact on outcome. Blood 2012; 120, (abstract 2503).

  6. Virtaneva K, Wright FA, Tanner SM, Yuan B, Lemon WJ, Caligiuri MA et al. Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. Proc Natl Acad Sci USA 2001; 98: 1124–1129.

    Article  CAS  Google Scholar 

  7. Schoch C, Kohlmann A, Dugas M, Kern W, Schnittger S, Haferlach T . Impact of trisomy 8 on expression of genes located on chromosome 8 in different AML subgroups. Genes Chromosomes Cancer 2006; 45: 1164–1168.

    Article  CAS  Google Scholar 

  8. Garzon R, Volinia S, Liu C-G, Fernandez-Cymering C, Palumbo T, Pichiorri F et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008; 111: 3183–3189.

    Article  CAS  Google Scholar 

  9. Caligiuri MA, Strout MP, Schichman SA, Mrózek K, Arthur DC, Herzig GP et al. Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res 1996; 56: 1418–1425.

    CAS  Google Scholar 

  10. Dicker F, Haferlach C, Kern W, Haferlach T, Schnittger S . Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. Blood 2007; 110: 1308–1316.

    Article  CAS  Google Scholar 

  11. Schwind S, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Holland KB et al. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010; 116: 5660–5669.

    Article  CAS  Google Scholar 

  12. Marcucci G, Maharry K, Wu Y-Z, Radmacher MD, Mrózek K, Margeson D et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010; 28: 2348–2355.

    Article  CAS  Google Scholar 

  13. Baldus CD, Liyanarachchi S, Mrózek K, Auer H, Tanner SM, Guimond M et al. Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: amplification discloses overexpression of APP, ETS2, and ERG genes. Proc Natl Acad Sci USA 2004; 101: 3915–3920.

    Article  CAS  Google Scholar 

  14. Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S et al. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA 2011; 305: 59–67.

    Article  CAS  Google Scholar 

  15. Yamakuchi M, Lotterman CD, Bao C, Hruban RH, Karim B, Mendell JT et al. P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci USA 2010; 107: 6334–6339.

    Article  CAS  Google Scholar 

  16. García-Ortí L, Cristóbal I, Cirauqui C, Guruceaga E, Marcotegui N, Calasanz MJ et al. Integration of SNP and mRNA arrays with microRNA profiling reveals that MiR-370 is upregulated and targets NF1 in acute myeloid leukemia. PLoS One 2012; 7: e47717.

    Article  Google Scholar 

  17. Garzon R, Pichiorri F, Palumbo T, Visentini M, Aqeilan R, Cimmino A et al. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene 2007; 26: 4148–4157.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The Cancer and Leukemia Group B (CALGB) institutions, principal investigators and cytogeneticists participating in this study are provided in the Supplementary Information. The research was supported in part by National Cancer Institute, Bethesda, MD grants CA101140, CA140158, CA114725, CA129657, CA16058, CA77658, The Coleman Leukemia Research Foundation, the Deutsche Krebshilfe—Dr Mildred Scheel Foundation (to HB) and the Research Committee of the University Freiburg, Germany (to HB), the Pelotonia Fellowship Program (to A-KE), and the Conquer Cancer Foundation (to JHM). The research for CALGB 8461, 20202 and 9665 (Alliance) was supported, in part, by grants from the National Cancer Institute (CA31946) to the Alliance for Clinical Trials in Oncology (Monica M Bertagnolli, Chair) and to the Alliance Statistics and Data Center (Daniel J Sargent, CA33601). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute. We thank Donna Bucci and the CALGB Leukemia Tissue Bank at The Ohio State University Comprehensive Cancer Center, Columbus, OH, for sample processing and storage services, Colin G Edwards, PhD, Lisa J Sterling and Christine Finks for data management, and Dean Margeson and Kelsi B Holland for assistance in the statistical analyses. Moreover, we thank Stephan M Tanner, PhD and Albert de la Chapelle, MD, PhD for scientific discussions.

Author information

Author notes

  1. H Becker

    Present address: 10Current address: Department of Internal Medicine I, Medical Center, University of Freiburg, Freiburg, Germany.,

  2. G Marcucci and C D Bloomfield: These senior authors contributed equally to this work.

Authors and Affiliations

  1. The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA

    H Becker, K Maharry, K Mrózek, S Volinia, A-K Eisfeld, M D Radmacher, J Kohlschmidt, K H Metzeler, S Schwind, S P Whitman, J H Mendler, Y-Z Wu, D Nicolet, P Paschka, M A Caligiuri, G Marcucci & C D Bloomfield

  2. Alliance for Clinical Trials in Oncology Statistics and Data Center, Mayo Clinic, Rochester, MN, USA

    K Maharry & J Kohlschmidt

  3. Comprehensive Cancer Center, Wake Forest University, Winston-Salem, NC, USA

    B L Powell

  4. Department of Internal Medicine, University of Iowa, Iowa City, IA, USA

    T H Carter

  5. Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA

    M Wetzler

  6. Monter Cancer Center, Hofstra North Shore-Long Island Jewish School of Medicine, Lake Success, NY, USA

    J E Kolitz

  7. Department of Genetics, University of Alabama at Birmingham, Birmingham, AL, USA

    A J Carroll

  8. Department of Medicine and Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA

    M R Baer

  9. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

    R M Stone

Authors
  1. H Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Maharry
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Mrózek
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Volinia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A-K Eisfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M D Radmacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J Kohlschmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K H Metzeler
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S Schwind
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S P Whitman
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. J H Mendler
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Y-Z Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. D Nicolet
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. P Paschka
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. B L Powell
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. T H Carter
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. M Wetzler
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. J E Kolitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. A J Carroll
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. M R Baer
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. M A Caligiuri
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. R M Stone
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. G Marcucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. C D Bloomfield
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

for the Alliance for Clinical Trials in Oncology

Corresponding authors

Correspondence to G Marcucci or C D Bloomfield.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Author contributions

HB, K Maharry, K Mrózek, SV, MDR, GM and CDB contributed to the design and analysis of this study and the writing of this manuscript, and all authors agreed on the final version; HB, A-KE, KHM, SS, SPW, JHM, Y-ZW and PP carried out laboratory-based research; K Maharry, SV, MDR, JK and DN performed statistical analyses; and BLP, THC, MW, JEK, AJC, MRB, MAC, RMS, GM and CDB were involved directly or indirectly in the care of patients and/or sample procurement.

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Becker, H., Maharry, K., Mrózek, K. et al. Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8. Leukemia 28, 1754–1758 (2014). https://doi.org/10.1038/leu.2014.114

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2014.114

This article is cited by

Search

Advanced search

Quick links